We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+20.49%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$1.73B
AUM Growth
+$225M
Cap. Flow
+$22.1M
Cap. Flow %
1.27%
Top 10 Hldgs %
47.96%
Holding
98
New
32
Increased
17
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$41.6M
2
WSM icon
Williams-Sonoma
WSM
+$31.1M
3
DECK icon
Deckers Outdoor
DECK
+$29.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$28.6M
5
AZO icon
AutoZone
AZO
+$28.5M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$50.8M
2
ENR icon
Energizer
ENR
+$34.9M
3
FL
Foot Locker
FL
+$26.5M
4
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$26.5M
5
TGT icon
Target
TGT
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 45.34%
2 Miscellaneous 28.01%
3 Consumer Discretionary 17.1%
4 Consumer Staples 5.85%
5 Technology 2.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TGTX icon
51
TG Therapeutics
TGTX
$8.55B
$8.88M 0.51%
+800,000
New +$6.08M
VXRT
52
DELISTED
Vaxart
VXRT
$8.83M 0.51%
25,200,000
+1,200,000
+5% +$397K
ADMS
53
DELISTED
Adamas Pharmaceuticals
ADMS
$8.32M 0.48%
2,196,000
+1,660,000
+310% +$7.95M
TPR icon
54
Tapestry
TPR
$23.5B
$7.88M 0.45%
+292,046
New +$7.61M
AYTU icon
55
AYTU BioPharma
AYTU
$23.8M
$7.73M 0.45%
39,750
+14,150
+55% +$2.72M
CI icon
56
Cigna
CI
$73.2B
$7.57M 0.44%
+37,000
New +$6.78M
DNKN
57
DELISTED
Dunkin' Brands Group, Inc.
DNKN
$7.4M 0.43%
+98,000
New +$7.41M
BIO icon
58
Bio-Rad Laboratories Class A
BIO
$10.2B
$7.4M 0.43%
+20,000
New +$7.05M
AMZN icon
59
Amazon
AMZN
$2.77T
$7.39M 0.43%
80,000
+20,000
+33% +$1.77M
ALXN
60
DELISTED
Alexion Pharmaceuticals
ALXN
$7.35M 0.42%
+68,000
New +$7.27M
MRK icon
61
Merck
MRK
$367B
$7.28M 0.42%
83,840
-58,688
-41% -$4.82M
KMX icon
62
CarMax
KMX
$8.6B
$7.19M 0.41%
+82,000
New +$7.71M
OLLI icon
63
Ollie's Bargain Outlet
OLLI
$4.57B
$7.01M 0.4%
+107,339
New +$6.8M
ACET icon
64
Adicet Bio
ACET
$91.2M
$5.25M 0.3%
+31,464
New +$15.9M
NERV icon
65
Minerva Neurosciences
NERV
$210M
$3.98M 0.23%
+70,000
New +$3.09M
NNBR icon
66
NN Inc
NNBR
$311M
$2.7M 0.16%
+292,021
New +$2.34M
ALIM
67
DELISTED
Alimera Sciences
ALIM
$2.58M 0.15%
340,000
-55,733
-14% -$333K
CHRN
68
ChronoScale Holdings
CHRN
$3.14B
$1.22M 0.07%
+13,842
New +$1.71M
XYLO
69
DELISTED
Xylo Technologies
XYLO
$742K 0.04%
32,143
– –
TTPH
70
DELISTED
Tetraphase Pharmaceuticals, Inc.
TTPH
$420K 0.02%
+149,507
New +$480K
CRDF icon
71
Cardiff Oncology
CRDF
$86.4M
$103K 0.01%
+82,928
New +$118K
BBWI icon
72
Bath & Body Works
BBWI
$3.79B
– –
-507,170
Closed -$8.03M
CTXR icon
73
Citius Pharmaceuticals
CTXR
$16.5M
– –
-87,895
Closed -$2.47M
ENR icon
74
Energizer
ENR
$1.45B
– –
-800,000
Closed -$34.9M
FL
75
DELISTED
Foot Locker
FL
– –
-615,000
Closed -$26.5M
1 2
3
4

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Armistice Capital held 98 positions worth $1.73B, up 15% from $1.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Armistice Capital's Q4 2019 filing shows 32 new, 17 increased, 16 reduced and 27 closed positions. Its largest new stake was Supernus Pharmaceuticals: 1,712,000 shares worth $40.6M. The largest sale was Celgene Corp, an estimated $50.8M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 42% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Armistice Capital's largest Q4 2019 buy was Supernus Pharmaceuticals: 1,712,000 shares worth $40.6M.
  • Armistice Capital added most to PTC Therapeutics in Q4 2019, an estimated $26.4M increase.
  • Armistice Capital's biggest Q4 2019 reduction was Kraft Heinz, cutting an estimated $24.5M.
  • Armistice Capital fully exited Celgene Corp in Q4 2019, selling an estimated $50.8M.
  • Armistice Capital's ten largest holdings make up 48% of its $1.73B portfolio in Q4 2019.
  • Armistice Capital opened 32 new positions and closed 27 in Q4 2019.
  • Armistice Capital's portfolio value rose 15% quarter-over-quarter to $1.73B.

Based on Armistice Capital's 13F filing for Q4 2019, filed 14 Feb 2020.